Progress against cancer doesn’t always arrive as headlines. Often, it shows up quietly in longer lives, better tolerability, and higher expectations for what treatment can deliver. The fight against ...

Kerry Rogers, MD, breaks down the clinical and lifestyle factors that drive frontline treatment selection between BTK ...

Researchers review available clinical evidence for retreatment with venetoclax, alone or in combination, in patients with relapsed chronic lymphocytic leukemia.

Treatment with so-called BTK inhibitors has improved the prognosis for people with chronic lymphocytic leukemia (CLL). At the same time, these drugs affect the immune system and may cause side effects ...

Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL) are types of slow-growing cancers that affect a type of white blood cell called a lymphocyte. Lymphocytes are cells that help ...

IntroductionBruton’s tyrosine kinase (BTK) is at the core of present day treatment in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) which in turn is redefining first line and ...

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of ...

Chronic lymphocytic leukemia (CLL) is one of the most common types of leukemia in adults and is currently incurable. Dr. Brian Koffman, chief medical officer and executive vice president of the CLL ...

Researchers sought to compare the safety and effectiveness of zanubrutinib and ibrutinib in routine clinical practice.

Monthly IVIG reduced grade ≥2 infections from 100% pre-treatment to 33% post-treatment, yielding a 67% relative and absolute risk reduction with strong statistical significance. Baseline IgG and IgA ...